PriceTargets.com logo

BiondVax Pharmaceuticals - BVXV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 09/6/2023 04:59 PM ET
+0 (0.00%)
Get New BiondVax Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BVXV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BVXV

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for BiondVax Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for BVXV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in BiondVax Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2022AegisInitiated CoverageBuy$70.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
BiondVax Pharmaceuticals logo
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.36
Low: $1.26
High: $1.59

52 Week Range

Now: N/A

Volume

23,000 shs

Average Volume

127,289 shs

Market Capitalization

$2.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.37

Frequently Asked Questions

What sell-side analysts currently cover shares of BiondVax Pharmaceuticals?

The following equities research analysts have issued research reports on BiondVax Pharmaceuticals in the last twelve months: StockNews.com.
View the latest analyst ratings for BVXV.

What is the current price target for BiondVax Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for BiondVax Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BiondVax Pharmaceuticals in the next year.
View the latest price targets for BVXV.

What is the current consensus analyst rating for BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BVXV.

What other companies compete with BiondVax Pharmaceuticals?

Other companies that are similar to BiondVax Pharmaceuticals include Eiger BioPharmaceuticals, Revelation Biosciences, 9 Meters Biopharma, Bellicum Pharmaceuticals and Bionomics. Learn More about companies similar to BiondVax Pharmaceuticals.

How do I contact BiondVax Pharmaceuticals' investor relations team?

BiondVax Pharmaceuticals' physical mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company's listed phone number is 9723029302529 and its investor relations email address is [email protected]. The official website for BiondVax Pharmaceuticals is www.biondvax.com. Learn More about contacing BiondVax Pharmaceuticals investor relations.